PIRAMAL HEALTHCARE

PIRAMAL HEALTHCARE LTD
BSE: 500302 | NSE: PIRHEALTH | ISIN: INE140A01024 |FV 2.00

Piramal Healthcare is among the leading producers of halothane and isoflurane. With its latest acquistion of Minrad Internation (a generic inhalation anaesthetics company), Piramal Healthcare is set to strengthen its global presence in the critical care space, as the deal will give Piramal immediate access into the US market for the country's largest selling inhalation anaethetic sevaflurane.
Piramal has been on the prowl for quite sometime with its acquisition of Rhodia's Inhalation Anaesthetics business in 2004 and 'Haemaccel' brand acquisition from PlasmaSelectAG of Germany.


RECOMMENDATIONS :
With the continued favourable environment for CRAMS business due to its inherent cost advantages, and strong MNC relations, Piramal will continue to be a big beneficiary of increased outsourcing from India. Its domestic business too continues to be strong and steady.
The Company should outperform its peers comfortably and can be considered for accumulation at every declines.


Other Brokerages Targets :
Angel Broking has maintained its Buy rating on Piramal Healthcare with a target price of Rs 340.
Kotak Securities has maintained its Accumulate rating on Piramal Healthcare with a target price of Rs 313.
Sharekhan has maintained its buy rating on Piramal Healthcare with a target of Rs 434 in its December 23, 2008 research report.
SBICAP Securities
has maintained its buy rating on Piramal Healthcare with a target of Rs 360.
Motilal Oswal has maintained its buy rating on Piramal Healthcare.
Religare research has maintained buy rating on Piramal Healthcare with target price of Rs 412.

Also visit my other blogs namely
http://goodfundadvisor.blogspot.com/
http://goodtravelplanner.blogspot.com/
http://indiahotelstariff.blogspot.com/